Compare TK & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TK | SGP |
|---|---|---|
| Founded | 1973 | 2019 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 937.1M | 932.9M |
| IPO Year | 1995 | N/A |
| Metric | TK | SGP |
|---|---|---|
| Price | $12.00 | $22.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | ★ 544.1K | 100.8K |
| Earning Date | 05-06-2026 | 03-26-2026 |
| Dividend Yield | ★ 16.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.65 | $22.41 |
| 52 Week High | $13.76 | $30.56 |
| Indicator | TK | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 54.04 | 31.50 |
| Support Level | $9.11 | N/A |
| Resistance Level | $13.76 | $29.83 |
| Average True Range (ATR) | 0.43 | 1.78 |
| MACD | -0.02 | -0.39 |
| Stochastic Oscillator | 62.56 | 10.49 |
Teekay Corp Ltd provides international crude oil marine transportation and other marine services. It also offers offshore oil production, storage, and offloading services, under long-term, fixed-rate contracts. The company has two primary lines of business: Marine services and tankers. It manages these businesses for the benefit of all stakeholders. The company serves energy and utility companies, oil traders, large oil and LNG consumers, petroleum product producers, government agencies, and various other entities that depend upon marine transportation.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.